Journal
FUTURE MEDICINAL CHEMISTRY
Volume 8, Issue 8, Pages 899-917Publisher
FUTURE SCI LTD
DOI: 10.4155/fmc-2016-0022
Keywords
boron neutron capture therapy; gadolinium neutron capture therapy; Gd contrast agents; MRI; nanosized Gd agents; tumor treatment
Categories
Funding
- MIUR (PRIN) [2012SK7ASN]
- AIRC investigator Grant [IG2013]
- National Institute of Nuclear Physics (INFN), Italy
Ask authors/readers for more resources
Gadolinium neutron capture therapy (Gd-NCT) is currently under development as an alternative approach for cancer therapy. All of the clinical experience to date with NCT is done with B-10, known as boron neutron capture therapy (BNCT), a binary treatment combining neutron irradiation with the delivery of boron-containing compounds to tumors. Currently, the use of Gd for NCT has been getting more attention because of its highest neutron cross-section. Although Gd-NCT was first proposed many years ago, its development has suffered due to lack of appropriate tumor-selective Gd agents. This review aims to highlight the recent advances for the design, synthesis and biological testing of new Gd-and B-Gd-containing compounds with the task of finding the best systems able to improve the NCT clinical outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available